Lupus therapies (WP5560)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads

Therapeutic approaches in systemic lupus erythematosus (SLE) increasingly focus on modulating B and T cell activity. B cell–directed therapies involve targeting specific surface receptors such as CD19, CD20, CD22, CD38, and CD40, as well as blocking B cell-related cytokines like BAFF (B-cell activating factor, also known as TNFSF13B). T cell-focused strategies include blocking co-stimulatory pathways (e.g. CD40–CD40L, CD80/86–CD28, ICOS–ICOSL) and inhibiting pro-inflammatory cytokines, including IL-6, IL-12, IL-17, IL-23, and IFN-γ. Inspired by Figure 1 in Su et al. (2024).

For a description of pathway objects, see the WikiPathways Legend.

Authors

Eric Weitz and Egon Willighagen

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Cell Type Ontology

T cell glomerular cell dendritic cell macrophage plasma cell neutrophil B cell

Disease Ontology

lupus erythematosus

Pathway Ontology

drug pathway

Participants
Query Drugst.One

Label Type Compact URI Comment
Dapirolizumabpegol Metabolite drugbank:DB16131
Rituximab Metabolite drugbank:DB00073
Ocrelizumab Metabolite drugbank:DB11988
Obinutuzumab Metabolite drugbank:DB08935
Ofatumumab Metabolite drugbank:DB06650
Obexelimab Metabolite drugbank:DB15032 'XmAb5871' in source
Inebilizumab Metabolite drugbank:DB12530 'MEDI551' in source
Epratuzumab Metabolite drugbank:DB04958
Daratumumab Metabolite drugbank:DB09331
Mezagitamab Metabolite drugbank:DB16370
Belimumab Metabolite drugbank:DB08879
Ianalumab Metabolite drugbank:DB16666
Tabalumab Metabolite drugbank:DB11657
Telitacicept Metabolite drugbank:DB18312
Ustekinumab Metabolite drugbank:DB05679
Guselkumab Metabolite drugbank:DB11834
Secukinumab Metabolite drugbank:DB09029
Ianalumab Metabolite drugbank:DB16666 'VAY736' in source
Sirukumab Metabolite drugbank:DB14891 'CNTO 136' in source
Vobarilizumab Metabolite drugbank:DB14891 'ALX-0061' in source
Tocilizumab Metabolite drugbank:DB06273
Atacicept Metabolite drugbank:DB06399
Autoantibodies GeneProduct wikidata:Q785022
CD40 GeneProduct ensembl:ENSG00000101017
CD40LG GeneProduct ensembl:ENSG00000102245 'CD40L' in source
IL17A GeneProduct ensembl:ENSG00000112115 'IL17' in source
IL6 GeneProduct ensembl:ENSG00000136244
CD86 GeneProduct ensembl:ENSG00000114013
CD80 GeneProduct ensembl:ENSG00000121594
CD28 GeneProduct ensembl:ENSG00000178562
CD19 GeneProduct ensembl:ENSG00000177455
CD22 GeneProduct ensembl:ENSG00000012124
MS4A1 GeneProduct ensembl:ENSG00000156738 'CD20' in source
CD38 GeneProduct ensembl:ENSG00000004468
IL6R GeneProduct ensembl:ENSG00000160712
TNFSF13B GeneProduct ensembl:ENSG00000102524 'BAFF' in source
IL23A GeneProduct ensembl:ENSG00000110944
IL23B GeneProduct ensembl:ENSG00000113302
IL12A GeneProduct ensembl:ENSG00000168811 'IL17' in source
IL12B GeneProduct ensembl:ENSG00000113302 'IL17' in source
IL17B GeneProduct ensembl:ENSG00000127743 'IL17' in source
IL17C GeneProduct ensembl:ENSG00000124391 'IL17' in source
IL17D GeneProduct ensembl:ENSG00000172458 'IL17' in source
IL25 GeneProduct ensembl:ENSG00000166090 'IL17' in source
IL17F GeneProduct ensembl:ENSG00000112116 'IL17' in source
IFNG GeneProduct ensembl:ENSG00000111537
C1QA GeneProduct ensembl:ENSG00000173372
C1QB GeneProduct ensembl:ENSG00000173369
C1QC GeneProduct ensembl:ENSG00000159189
C2 GeneProduct ensembl:ENSG00000166278
C3 GeneProduct ensembl:ENSG00000125730
C4A GeneProduct ensembl:ENSG00000244731
C4B GeneProduct ensembl:ENSG00000224389

References

  1. Systemic lupus erythematosus: pathogenesis and targeted therapy. Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang Z, et al. Mol Biomed. 2024 Oct 30;5(1):54. PubMed Europe PMC Scholia